MEDINA has become an associate partner of this important European Alliance which aims to battle multi-drug resistant bacteria.
The emergence of multi-drug resistant bacteria represents a global public health crisis and demands the development of new antibiotics, preventive or alternative strategies as the R&D investment from large pharmaceutical companies is on the wane. Due to lack of attractiveness of investment in this therapeutic area, innovation is largely driven by biotech companies. Thus, European nations need to be more extensively engaged in supporting this innovation via new policies and R&D stimulating incentives.
The BEAM Alliance will work on regulation improvements and on the development of investment programs in Europe. Increasing the research and development of new products, it will also be able to conduct promotional actions for new products with good market viability.